Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Classement en actions #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Prix de l'action
$7.12
Dernière synchronisation: 2023-03-08
Capitalisation boursière
$117.03M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
GB
Échange F-star Therapeutics, Inc. (FSTX)

Catégorie

Historique du rendement du dividende pour F-star Therapeutics, Inc. (FSTX)
Le rendement du dividende (TTM) de F-star Therapeutics, Inc. (symbole boursier : FSTX) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de F-star Therapeutics, Inc. (FSTX) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH